Brain AtrophyNeurodegeneration A Neuropathologist Perspective Brain Volume Change Under Multiple Influences Brain AtrophyNeurodegeneration A Clinical Perspective Pathological Causes of Brain Atrophy in MS ID: 774944
Download Presentation The PPT/PDF document " What’s the Big Deal About Brain Atrop..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?
Slide2Slide3Brain Atrophy/Neurodegeneration: A Neuropathologist Perspective
Slide4Brain Volume Change: Under Multiple Influences
Slide5Brain Atrophy/Neurodegeneration:A Clinical Perspective
Slide6Pathological Causes of Brain Atrophy in MS
Slide7Mechanisms of Neurodegeneration in MS
Slide8Correlation Between Focal and Diffuse Pathological Changes
Slide9Detection of Brain Atrophy in MS Patients Using Imaging Techniques
Slide10Common Measures for Whole Brain and Regional Brain Atrophy
Slide11Brain Atrophy Is Related to Long-Term Disability in RRMS
Slide12GM and WM Volume Changes in Early RRMS
Slide13Pseudoatrophy After DMT Treatment
Slide14Effect of BRACE Therapies On Brain Volume Loss
Slide15Brain Volume Loss Outcomes: Results From the AFFIRM Trial
Slide16Alemtuzumab Brain Volume Loss Through Year 5
Slide17Teriflunomide Reduced Annual Brain Volume Loss Over 2 years in the TEMSO Study*
Slide18Reduction in PBVC With DMF: Significant in DEFINE But Not CONFIRM
Slide19ENDORSE Extension Trial Results
Slide20Fingolimod: Summary of Brain Volume Loss Data in FREEDOMS, FREEDOMS II, and TRANSFORMS
Slide21Sustained Reduction in Brain Volume Loss Over 4 Years
Slide22PREFERMS: Phase 4 Patient Outcomes on Fingolimod versus Platform Injectable DMTs
Slide23Contribution of Individual Components of NEDA-4 on Proportion of Patients Achieving NEDA
Slide24Predictive Value of NEDA for Disease Outcomes Over 6 Years
Slide25Types of Inflammation in MS
Slide26Evidence for Direct CNS Effects
Slide27Adding Brain Volume Loss to the Modified Rio Score System
Slide28Persistent MRI Lesion Activity and Brain Volume Loss as Predictors of Long-Term Disability Progression
Slide29Conclusions
Slide30Abbreviations
Slide31Abbreviations (cont)